Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma

被引：19
|
作者：
Chan, Kah-Lok [1 ]
Filshie, Robin [1 ]
Nandurkar, Harshal [1 ]
Quach, Hang [1 ]
机构：
[1] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 07期
关键词：
HEMOLYTIC-UREMIC SYNDROME; PATIENT;
D O I：
10.3109/10428194.2014.977887
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2185 / 2186
页数：2
相关论文
共 50 条
  • [31] Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma
    Ludwig, Heinz
    Drach, Johannes
    Graf, Helmut
    Lang, Alois
    Meran, Johannes Gobertus
    HAEMATOLOGICA, 2007, 92 (10) : 1411 - 1414
  • [32] Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
    Roussou, Maria
    Kastritis, Efstathios
    Migkou, Magdalini
    Psimenou, Erasmia
    Grapsa, Irini
    Matsouka, Charis
    Barmparousi, Despina
    Terpos, Evangelos
    Dimopoulos, Meletios Athanasios
    LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 890 - 895
  • [33] Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients
    Liu, Zhaoyun
    Shen, Hongli
    Han, Mei
    Zhao, Xianghong
    Liu, Hui
    Ding, Kai
    Song, Jia
    Fu, Rong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 130
  • [34] Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment
    Szturz, Petr
    Adam, Zdenek
    Vasku, Vladimir
    Feit, Josef
    Krejci, Marta
    Pour, Ludek
    Hajek, Roman
    Mayer, Jiri
    LEUKEMIA & LYMPHOMA, 2013, 54 (06) : 1324 - 1326
  • [35] OPTIMIZATION OF BORTEZOMIB-BASED COMBINATIVE REGIMEN IN ELDERLY RELAPSED MULTIPLE MYELOMA PATIENTS
    Zahradova, L.
    Hajek, R.
    Gregora, E.
    Schuetzova, M.
    Adam, Z.
    Pour, L.
    Krejci, M.
    Pavlicek, P.
    Koza, V.
    Krivanova, A.
    Sandecka, V.
    Kralova, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 383 - 383
  • [36] Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma
    Lamm, W.
    Drach-Schauer, B.
    Eder, S.
    Drach, J.
    ONCOLOGY, 2013, 85 (04) : 223 - 227
  • [37] The effect of bortezomib monotherapy and bortezomib-based regimens on bone metabolism in patients with relapsed/refractory multiple myeloma
    Terpos, E.
    Heath, D. J.
    Zervas, K.
    Anagnostopoulos, A.
    Katodritou, E.
    Christoulas, D.
    Pouli, A.
    Chantry, A.
    Anargyrou, K.
    Kastritis, E.
    Verrou, E.
    Tsionos, K.
    Croucher, P.
    Dimopoulus, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 133 - 134
  • [38] Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma
    Sopena, Maria
    Clavero, Estela Martin
    Villa, Paula
    Martinez-Lopez, Joaquin
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (03) : 147 - 154
  • [39] Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving bortezomib-based therapy for multiple myeloma
    Zhou, Xin
    Wang, Jing
    Xia, Jun
    Cheng, Feng
    Mao, Jingjue
    Zhu, Jianwei
    Guo, Hongfeng
    CANCER BIOMARKERS, 2018, 22 (01) : 43 - 48
  • [40] The treatment of relapsed and refractory myeloma: Focus on bortezomib and bortezomib-based combinations
    Richardson, P.
    Schlossman, R.
    Ghobrial, I.
    Mitsiades, C.
    Hicleshima, T.
    Chauhan, D.
    Munshi, N.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 21 - 22
12345